Equities research analysts expect Sarepta Therapeutics Inc (NASDAQ:SRPT) to announce ($0.67) earnings per share for the current quarter, Zacks Investment Research reports. Nine analysts have made estimates for Sarepta Therapeutics’ earnings, with estimates ranging from ($1.03) to ($0.32). Sarepta Therapeutics reported earnings of ($0.37) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 81.1%. The firm is scheduled to issue its next quarterly earnings report on Thursday, March 7th.
According to Zacks, analysts expect that Sarepta Therapeutics will report full-year earnings of ($1.94) per share for the current fiscal year, with EPS estimates ranging from ($2.30) to ($1.61). For the next financial year, analysts anticipate that the business will report earnings of ($1.89) per share, with EPS estimates ranging from ($2.96) to ($0.45). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Sarepta Therapeutics.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, October 24th. The biotechnology company reported ($1.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.86) by ($0.29). Sarepta Therapeutics had a negative net margin of 89.46% and a negative return on equity of 23.67%. The business had revenue of $78.49 million during the quarter, compared to analyst estimates of $78.84 million.
In other news, CEO Douglas S. Ingram bought 16,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 15th. The shares were purchased at an average price of $125.26 per share, with a total value of $2,004,160.00. Following the purchase, the chief executive officer now owns 399,250 shares in the company, valued at $50,010,055. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the stock in a transaction dated Thursday, November 1st. The stock was sold at an average price of $140.50, for a total value of $936,713.50. Following the transaction, the director now directly owns 126,534 shares in the company, valued at approximately $17,778,027. The disclosure for this sale can be found here. 7.90% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. First Quadrant L P CA purchased a new stake in Sarepta Therapeutics during the 3rd quarter worth about $130,000. Rockefeller Capital Management L.P. purchased a new stake in Sarepta Therapeutics during the 2nd quarter worth about $162,000. Ffcm LLC purchased a new stake in Sarepta Therapeutics during the 3rd quarter worth about $162,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new stake in Sarepta Therapeutics during the 2nd quarter worth about $185,000. Finally, Keybank National Association OH purchased a new stake in Sarepta Therapeutics during the 2nd quarter worth about $206,000. 89.84% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Sarepta Therapeutics stock opened at $125.46 on Friday. Sarepta Therapeutics has a 52 week low of $50.68 and a 52 week high of $176.50. The firm has a market capitalization of $8.89 billion, a PE ratio of -76.50 and a beta of 1.59. The company has a current ratio of 8.85, a quick ratio of 7.84 and a debt-to-equity ratio of 0.65.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Recommended Story: Calculate Your Return on Investment (ROI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.